You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
The test uses prognostic markers to group women based on their risk of 10-year recurrence of ductal carcinoma in situ.
In response to CMS reopening its national coverage determination to address its germline testing policy, stakeholders point out areas of concern and confusion.
